More than 90 percent of people with the genetic condition Huntingtons disease develop chorea involuntary movements that can interfere with daily activities, communication, and independence. While ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo, according to a recent international study led by ...

Ingrezza (valbenazine) is a medication used to treat tardive dyskinesia (TD) and chorea associated with Huntington’s disease. These conditions cause involuntary movements like twitching, jerking, or ...

Motor symptoms of Huntington's disease (HD) are so central to the genetic neurodegenerative disease that it was long called Huntington's chorea. However, they're often untreated, despite a growing ...

A drug widely available in Europe and Canada – but not the United States – dramatically eases one of the most disabling symptoms of Huntington’s disease, involuntary writhing movements known as chorea ...

A new drug was approved for Huntington's chorea in 2023, and novel insights about Huntington's disease emerged in new research. Valbenazine for Huntington's Chorea In August, the FDA expanded the ...

A drug currently approved for tardive dyskinesia (TD) is also effective at treating Huntington's disease (HD)–associated chorea, a movement disorder that affects most patients with HD, new phase 3 ...

‌Chorea is a movement disorder that stems from something wrong with the basal ganglia nerve structure deep in your brain. It causes involuntary movements of the hands, feet, and face. These movements ...

Many people with Huntington’s disease experience chorea, but they are separate conditions. Chorea is one of several common symptoms of Huntington’s disease, but it has other potential causes. Chorea ...

People with uncontrolled movement problems can have a harder time doing everyday tasks such as speaking, reading, writing, and cooking, which can cause a loss of independence. This may cause people to ...

Credit: Neurocrine Biosciences. Nearly half of patients receiving Ingrezza saw a more than 40% reduction in Huntington disease chorea severity by the end of the treatment period. The Food and Drug ...